e-learning
resources
London 2016
Tuesday, 06.09.2016
Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia
Adrian Ceccato (Ituzaingo, Argentina), Adrian Ceccato, Miquel Ferrer, Albert Gabarrus, Oriol Sibilla, Eva Polverino, Catia Cilloniz, Carlos Agusti, Francisca Lopez, Michael Niederman, Antoni Torres
Source:
International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Session:
Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Session type:
Oral Presentation
Number:
3328
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Adrian Ceccato (Ituzaingo, Argentina), Adrian Ceccato, Miquel Ferrer, Albert Gabarrus, Oriol Sibilla, Eva Polverino, Catia Cilloniz, Carlos Agusti, Francisca Lopez, Michael Niederman, Antoni Torres. Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia. Eur Respir J 2016; 48: Suppl. 60, 3328
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia?
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Factors affecting treatment success in community acquired pneumonia (CAP)
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries?
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Surfactant-enforced treatment of
pseudomonas
-induced pneumonia
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013
Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Colistin therapy for nosocomial pneumonia and nephrotoxicity
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia?
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Development of an antibody therapy for the treatment of pneumonia
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
Effectiveness of immune stimulatory therapy in patient with severe community-acquired pneumonia (CAP)
Source: International Congress 2014 – Different interesting issues in respiratory infections: 1
Year: 2014
Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia?
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Could the early administration of antibiotics before admission improve the prognosis of pneumonia?
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept